MCID: SZR001
MIFTS: 60

Sezary's Disease

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Sezary's Disease

MalaCards integrated aliases for Sezary's Disease:

Name: Sezary's Disease 12 15 17
Sezary Syndrome 12 74 52 25 58 29 54 6 43 71
Sezary's Lymphoma 52 25
Sézary Syndrome 52 25
Sezary Erythroderma 25
Sezary Lymphoma 58
Sezary Disease 12

Characteristics:

Orphanet epidemiological data:

58
sezary syndrome
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: <1/1000000 (United States),<1/1000000 (Norway); Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare skin diseases
Rare haematological diseases


Summaries for Sezary's Disease

Genetics Home Reference : 25 Sézary syndrome is an aggressive form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. In Sézary syndrome, the cancerous T cells, called Sézary cells, are present in the blood, skin, and lymph nodes. A characteristic of Sézary cells is an abnormally shaped nucleus, described as cerebriform. People with Sézary syndrome develop a red, severely itchy rash (erythroderma) that covers large portions of their body. Sézary cells are found in the rash. However, the skin cells themselves are not cancerous; the skin problems result when Sézary cells move from the blood into the skin. People with Sézary syndrome also have enlarged lymph nodes (lymphadenopathy). Other common signs and symptoms of this condition include hair loss (alopecia), skin swelling (edema), thickened skin on the palms of the hands and soles of the feet (palmoplantar keratoderma), abnormalities of the fingernails and toenails, and lower eyelids that turn outward (ectropion). Some people with Sézary syndrome are less able to control their body temperature than people without the condition. The cancerous T cells can spread to other organs in the body, including the lymph nodes, liver, spleen, and bone marrow. In addition, affected individuals have an increased risk of developing another lymphoma or other type of cancer. Sézary syndrome most often occurs in adults over age 60 and usually progresses rapidly; historically, affected individuals survived an average of 2 to 4 years after development of the condition, although survival has improved with newer treatments. Although Sézary syndrome is sometimes referred to as a variant of another cutaneous T-cell lymphoma called mycosis fungoides, these two cancers are generally considered separate conditions.

MalaCards based summary : Sezary's Disease, also known as sezary syndrome, is related to cutaneous t cell lymphoma and exanthem, and has symptoms including pruritus An important gene associated with Sezary's Disease is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Busulfan and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone, and related phenotypes are dry skin and pruritus

NIH Rare Diseases : 52 Sezary syndrome is an aggressive form of cutaneous T-cell lymphoma which is a group of disorders that occur when T-cells (a type of white blood cell ) become cancerous and affect the skin. It is characterized by a widespread red rash that may cover most of the body, the presence of cancerous T cells (called Sezary cells) in the blood, and abnormally enlarged lymph nodes . Other signs and symptoms may include intense itchiness, scaling and peeling of the skin; fever; weight loss; hair loss; outward turning of the eyelids (ectropion); palmoplantar keratoderma ; malformation of the nails; and hepatosplenomegaly . The exact cause of Sezary syndrome is currently unknown. Treatment varies based on the signs and symptoms present in each person and the severity of the condition.

Wikipedia : 74 Sézary disease is a type of cutaneous lymphoma that was first described by Albert Sézary. The affected... more...

Related Diseases for Sezary's Disease

Diseases related to Sezary's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 340)
# Related Disease Score Top Affiliating Genes
1 cutaneous t cell lymphoma 33.3 IL7 IL5 IL4 IL2RA IL2 IFNA1
2 exanthem 31.4 TNFRSF1B IL2 IFNA1 CTLA4
3 dermatitis 31.3 IL5 IL4 IL2 CTLA4 CCR4 CCR10
4 herpes zoster 31.3 TNFRSF1B IL2 IFNA1
5 primary cutaneous t-cell lymphoma 31.3 PLS3 IL2RA
6 skin disease 31.3 TNFRSF1B MIR17 IL7 IL5 IL4 IL2
7 allergic hypersensitivity disease 31.2 IL5 IL4 IL2 CD28
8 acute graft versus host disease 31.2 IL4 IL2RA IL2
9 peripheral nervous system disease 31.1 TNFRSF1B MIR342 IL4 IL2 DPP4
10 leishmaniasis 31.1 IL5 IL4 IL2RA IL2 CTLA4 CD28
11 adult t-cell leukemia 31.1 IL2RA IL2 IFNA1 CTLA4 CD7 CCR4
12 diphtheria 31.1 IL5 IL4 IL2RA IL2 IFNA1
13 cutaneous leishmaniasis 31.1 IL5 IL4 IL2
14 leukemia, chronic lymphocytic 31.1 MIR223 MIR17 IL7 IL4 IL2RA IL2
15 dermatitis, atopic 31.0 IL5 IL4 IL2RA IL2 CTLA4 CCR4
16 t-cell lymphoblastic leukemia/lymphoma 31.0 MIR17 IL5 IL2RA IL2 CD7 CD28
17 contact dermatitis 31.0 IL5 IL4 IL2 CCR10
18 chickenpox 31.0 TNFRSF1B IL4 IL2 IFNA1 CTLA4
19 t-cell adult acute lymphocytic leukemia 31.0 IL2 CD7 CCR4
20 psoriasis 31.0 TNFRSF1B MIR17 IL7 IL5 IL4 IL2RA
21 lymphoma, non-hodgkin, familial 30.9 TNFRSF1B MIR342 MIR17 IL7 IL4 IL2RA
22 t-cell acute lymphoblastic leukemia 30.9 MIR223 IL7 IL4 IL2RA IL2 CTLA4
23 uveitis 30.9 TNFRSF1B IL4 IL2RA IL2 CTLA4
24 hairy cell leukemia 30.9 IL2RA IL2 IFNA1
25 lymphopenia 30.9 IL7 IL4 IL2RA IL2 CTLA4 BCL10
26 severe combined immunodeficiency 30.9 IL7 IL5 IL4 IL2RA IL2 DPP4
27 hypereosinophilic syndrome 30.8 IL5 IL4 IL2RA IL2 IFNA1
28 erythema multiforme 30.8 IL5 IL4 IL2
29 folliculitis 30.8 IL5 IL4 IL2RA
30 thrombocytopenia 30.8 IL7 IL4 IL2 IFNA1 CTLA4
31 arthritis 30.8 TNFRSF1B STAT4 IL4 CTLA4 CD28
32 alopecia areata 30.8 IL4 IL2RA IL2 CTLA4
33 sarcoidosis 1 30.8 TNFRSF1B IL2RA IL2 CD28
34 autoimmune disease 30.8 TNFRSF1B STAT4 IL5 IL4 IL2RA IL2
35 acquired immunodeficiency syndrome 30.8 TNFRSF1B IL2RA IL2 IFNA1
36 myeloma, multiple 30.8 MIR342 MIR17 IL7 IL4 IL2 IFNA1
37 immune deficiency disease 30.8 IL7 IL4 IL2RA IL2 IFNA1 CD28
38 visceral leishmaniasis 30.7 IL4 IL2 CD28
39 precursor t-cell acute lymphoblastic leukemia 30.7 IL7 CD7 BCL10
40 mycosis fungoides 30.7 TNFRSF1B PLS3 IL7 IL5 IL4 IL2RA
41 food allergy 30.7 IL5 IL4 CTLA4
42 leukemia, acute lymphoblastic 30.7 MIR223 MIR17 IL7 IL2 CD7
43 diabetes mellitus, type i 30.6 IL5 IL4 IL2RA IL2 IFNA1 DPP4
44 aspergillosis 30.1 TNFRSF1B IL5 IL4
45 1-chloro-2,4-dinitrobenzene allergic contact dermatitis 10.8 IL4 IL2
46 esophageal tuberculosis 10.8 TNFRSF1B IL2RA CTLA4
47 atopic keratoconjunctivitis 10.7 IL5 IL4 IL2
48 keratoconjunctivitis 10.7 IL5 IL4 IL2
49 b-cell expansion with nfkb and t-cell anergy 10.7 IL2RA IL2 CD28
50 autoimmune disease of eyes, ear, nose and throat 10.7 IL4 IL2 CTLA4

Graphical network of the top 20 diseases related to Sezary's Disease:



Diseases related to Sezary's Disease

Symptoms & Phenotypes for Sezary's Disease

Human phenotypes related to Sezary's Disease:

58 31 (show all 28)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dry skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0000958
2 pruritus 58 31 hallmark (90%) Very frequent (99-80%) HP:0000989
3 neoplasm of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0008069
4 lymphadenopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0002716
5 erythroderma 58 31 hallmark (90%) Very frequent (99-80%) HP:0001019
6 lichenification 58 31 hallmark (90%) Very frequent (99-80%) HP:0100725
7 cutaneous t-cell lymphoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0012192
8 abnormal lymphocyte morphology 31 hallmark (90%) HP:0004332
9 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
10 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
11 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
12 palmoplantar keratoderma 58 31 frequent (33%) Frequent (79-30%) HP:0000982
13 alopecia 58 31 frequent (33%) Frequent (79-30%) HP:0001596
14 nail dystrophy 58 31 frequent (33%) Frequent (79-30%) HP:0008404
15 abnormal facial shape 58 31 occasional (7.5%) Occasional (29-5%) HP:0001999
16 peripheral neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0009830
17 skeletal muscle atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0003202
18 edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0000969
19 tremor 58 31 occasional (7.5%) Occasional (29-5%) HP:0001337
20 gangrene 58 31 occasional (7.5%) Occasional (29-5%) HP:0100758
21 irregular hyperpigmentation 58 31 occasional (7.5%) Occasional (29-5%) HP:0007400
22 ectropion 58 31 occasional (7.5%) Occasional (29-5%) HP:0000656
23 abnormal immunoglobulin level 58 31 occasional (7.5%) Occasional (29-5%) HP:0010701
24 abnormal pleura morphology 31 occasional (7.5%) HP:0002103
25 abnormality of the pleura 58 Occasional (29-5%)
26 abnormality of the face 58 Frequent (79-30%)
27 lymphoma 58 Very frequent (99-80%)
28 abnormality of lymphocytes 58 Very frequent (99-80%)

UMLS symptoms related to Sezary's Disease:


pruritus

GenomeRNAi Phenotypes related to Sezary's Disease according to GeneCards Suite gene sharing:

26 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-10 9.72 DPP4 IL4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.72 IFNA1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-109 9.72 DPP4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.72 IFNA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-145 9.72 IFNA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.72 CCR10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 IFNA1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-175 9.72 IFNA1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-181 9.72 CCR10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.72 IL4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.72 CCR10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-191 9.72 CCR10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-209 9.72 IFNA1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.72 IL4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.72 IL4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.72 IL4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.72 IFNA1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.72 IL4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.72 IFNA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.72 IFNA1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.72 IFNA1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.72 CCR10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.72 DPP4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-95 9.72 DPP4

MGI Mouse Phenotypes related to Sezary's Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.03 BCL10 CCR10 CD28 CD7 CTLA4 DPP4
2 hematopoietic system MP:0005397 10.03 BCL10 CCR10 CCR4 CD28 CD7 CTLA4
3 immune system MP:0005387 9.83 BCL10 CCR10 CCR4 CD28 CD7 CTLA4
4 respiratory system MP:0005388 9.23 CCR4 CTLA4 DPP4 IL2 IL2RA IL4

Drugs & Therapeutics for Sezary's Disease

Drugs for Sezary's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 293)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4 55-98-1 2478
2
Gemcitabine Approved Phase 4 95058-81-4 60750
3
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 43805 6857599 5310940 9887054
4
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
7
Cytarabine Approved, Experimental, Investigational Phase 4 147-94-4, 65-46-3 6253
8
Etoposide Approved Phase 4 33419-42-0 36462
9
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
10
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
11
rituximab Approved Phase 4 174722-31-7 10201696
12
Ifosfamide Approved Phase 4 3778-73-2 3690
13
Epirubicin Approved Phase 4 56420-45-2 41867
14 Immunologic Factors Phase 4
15 Immunosuppressive Agents Phase 4
16 Thymoglobulin Phase 4
17 Immunoglobulins Phase 4
18 Antibodies Phase 4
19 Antibodies, Monoclonal Phase 4
20 Etoposide phosphate Phase 4
21
Isophosphamide mustard Phase 4 0
22 Orange Approved Phase 3
23
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
24
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
25
Ofloxacin Approved Phase 3 82419-36-1 4583
26
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
28
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
29
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
30
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
31
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
32
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
33
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
34
Captopril Approved Phase 3 62571-86-2 44093
35
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
36
Acyclovir Approved Phase 3 59277-89-3 2022
37
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
38
Mogamulizumab Approved, Investigational Phase 3 1159266-37-1
39
Methoxsalen Approved Phase 3 298-81-7 4114
40
Bexarotene Approved, Investigational Phase 3 153559-49-0 82146
41
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
42
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
43
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
44
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
45
Polyestradiol phosphate Approved Phase 3 28014-46-2
46
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
47 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
48 Anesthetics, Dissociative Phase 3
49 Antiviral Agents Phase 3
50 Adjuvants, Immunologic Phase 3

Interventional clinical trials:

(show top 50) (show all 358)
# Name Status NCT ID Phase Drugs
1 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
2 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
3 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
4 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Not yet recruiting NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
5 Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Terminated NCT01625455 Phase 4 Aprepitant;Placebo
6 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
9 A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
10 A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor Completed NCT00490776 Phase 2, Phase 3 LBH589
11 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
12 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
13 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
14 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
15 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
16 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
17 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
18 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
19 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
20 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
21 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
22 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
23 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
24 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
25 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
26 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
27 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
28 A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
29 Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma Active, not recruiting NCT01728805 Phase 3 Vorinostat
30 A Phase III Study of Lenalidomide Maintenance After Debulking Therapy in Patients With Advanced Cutaneous T-Cell Lymphoma Terminated NCT01098656 Phase 3 lenalidomide
31 Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
32 A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides Terminated NCT00056056 Phase 3 bexarotene;methoxypsoralen
33 Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Including Geriatric Assessment And Quality Of Life Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
34 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
35 Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in Refractory or Recurrent Advanced CTCL. A Randomized Study. Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
36 Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
37 A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2 bexarotene;methoxsalen
38 PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME Unknown status NCT00002557 Phase 2 CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
39 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
40 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
41 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
42 Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides or Sezary Syndrome Completed NCT00057967 Phase 2
43 Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level Completed NCT01396070 Phase 2 Brentuximab vedotin
44 A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome Completed NCT02243579 Phase 2
45 Phase II Trial of Tretinoin (TRA) in Patients With Mycosis Fungoides/Sezary Syndrome Completed NCT00002479 Phase 2 tretinoin
46 A Phase II Study of Bortezomib (VELCADE®) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00182637 Phase 2 bortezomib
47 Phase II Trial of Doxorubicin HCl Liposome Injection (Doxil®) in Advanced Stage Cutaneous T-Cell Lymphoma Followed by Bexarotene (Targretin®) Completed NCT00255801 Phase 2 Targretin® (bexarotene);pegylated liposomal doxorubicin hydrochloride
48 Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Sezary Syndrome Using Autologous Mature Dendritic Cells Completed NCT00099593 Phase 2
49 Phase 1-2 Multi-Center Study of Intravenous BCX-1777 in Patients With Refractory Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00061880 Phase 1, Phase 2 forodesine hydrochloride
50 Phase II Clinical Trial With Caelyx Mono-Chemotherapy in Patients With Advanced Mycosis Fungoides Stage IIb, IVa and IVb With or Without Previous Chemotherapy Completed NCT00074087 Phase 2 pegylated liposomal doxorubicin hydrochloride

Search NIH Clinical Center for Sezary's Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: sezary syndrome

Genetic Tests for Sezary's Disease

Genetic tests related to Sezary's Disease:

# Genetic test Affiliating Genes
1 Sezary Syndrome 29

Anatomical Context for Sezary's Disease

MalaCards organs/tissues related to Sezary's Disease:

40
T Cells, Skin, Bone, Bone Marrow, Lymph Node, Liver, Spleen

Publications for Sezary's Disease

Articles related to Sezary's Disease:

(show top 50) (show all 500)
# Title Authors PMID Year
1
MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. 61 46
20448109 2010
2
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 6
9989495 1999
3
Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines. 54 61
19239991 2008
4
Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. 61 54
18569641 2008
5
Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. 61 54
17975162 2007
6
Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. 61 54
17546636 2007
7
Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias. 54 61
16741518 2006
8
CCR10 is expressed in cutaneous T-cell lymphoma. 54 61
15700309 2005
9
Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. 54 61
15727636 2005
10
Aberrant expression of T-plastin in Sezary cells. 54 61
14612505 2003
11
Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. 61 54
12393503 2003
12
Diminished expression of the type II receptor for TGFbeta (TGFbetaRII) in T lymphocytes from patients with Sezary syndrome is not due to mutations in the receptor's poly-A tract: limitations of the standard RT-PCR in cDNA sequence analysis of homopolymeric base stretches. 61 54
12546068 2002
13
Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. 54 61
11368440 2001
14
Chromosomally clonal T cells in the skin, blood, or lymph nodes of two Sezary syndrome patients express CD45RA, CD45RO, CDw150, and interleukin-4, but no interleukin-2 or interferon-gamma. 54 61
11168816 2001
15
Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells. 54 61
9548535 1998
16
Hypertriglyceridemia during long-term interferon-alpha therapy in a series of hematologic patients. 54 61
9181461 1997
17
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. 54 61
8799169 1996
18
The clonal nature of circulating Sezary cells. 61 54
7492785 1995
19
Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. 54 61
7923918 1994
20
Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. 61 54
8080984 1994
21
Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review. 61
32435988 2020
22
Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma. 61
32438399 2020
23
Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma. 61
31682844 2020
24
[Atypical Sézary syndrome in a young subject]. 61
31806381 2020
25
The clinico-pathological spectrum of primary cutaneous lymphoma other than mycosis fungoides/Sezary syndrome. 61
31781845 2020
26
Combined total skin radiotherapy and immune checkpoint inhibitors: A promising potential treatment for mycosis fungoides and Sezary syndrome. 61
32077638 2020
27
[Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin]. 61
31959414 2020
28
Survival in Mycosis Fungoides and Sezary Syndrome: How Can We Predict Outcome? 61
31980062 2020
29
Haploidentical hematopoietic cell transplantation for mycosis fungoides/Sezary syndrome. 61
31452419 2020
30
Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome. 61
31591658 2020
31
Hepatic Infiltration with Malignant T-cells Manifesting as Impending Acute Liver Failure in Sezary Syndrome. 61
31934317 2020
32
Heterogeneity of T-cell receptor expression at transformation in mycosis fungoides/Sezary Syndrome (MF/SS). 61
31629155 2019
33
Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides. 61
31717353 2019
34
Usefulness of Flow Cytometry for the Detection of Cutaneous Localization in Malignant Hematologic Disorders. 61
31050147 2019
35
Loss of β-arrestin-2 gene and possible functional consequences on Sezary Syndrome. 61
31106661 2019
36
Merkel cell carcinoma arising in association with cutaneous T-cell lymphoma: A potential diagnostic pitfall. 61
30561044 2019
37
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. 61
29947731 2019
38
Extranodal lymphomas in the public health system in Chile: Analysis of 1251 patients from the National Adult Cancer Program. 61
30117170 2019
39
Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule. 61
30582018 2019
40
Sézary Syndrome, recent biomarkers and new drugs. 61
30525758 2019
41
Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma. 61
30529073 2019
42
Successful treatment of Sezary syndrome with extracorporeal photopheresis - The first attempt in India. 61
31360016 2019
43
Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma. 61
30596212 2019
44
Durable Control of Mycosis Fungoides after Sepsis: "Coley's Toxin?" Case Report and Review of the Literature. 61
31467737 2019
45
Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome. 61
30596221 2019
46
[Primary cutaneous lymphoma-a case series of 163 patients]. 61
29881891 2018
47
Health-related quality of life in patients with cutaneous T-cell lymphoma? 61
30074622 2018
48
Hypo-pigmented mycosis fungoides is a rare malignancy in pediatrics. 61
30695982 2018
49
Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. 61
30017383 2018
50
Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome. 61
30283619 2018

Variations for Sezary's Disease

ClinVar genetic disease variations for Sezary's Disease:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BCL10 NM_003921.5(BCL10):c.428del (p.Phe143fs)deletion Pathogenic 6260 rs587776632 1:85733584-85733584 1:85267901-85267901

Cosmic variations for Sezary's Disease:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87675933 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.12655C>T p.Q4219* 12:49032050-49032050 0

Copy number variations for Sezary's Disease from CNVD:

7 (show top 50) (show all 353)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 38537 10 103280000 105830000 Deletion ACTR1A Sezary syndrome
2 38538 10 103280000 105830000 Deletion ARL3 Sezary syndrome
3 38539 10 103280000 105830000 Deletion BTRC Sezary syndrome
4 38540 10 103280000 105830000 Deletion COL17A1 Sezary syndrome
5 38541 10 103280000 105830000 Deletion CYP17A1 Sezary syndrome
6 38542 10 103280000 105830000 Deletion FGF8 Sezary syndrome
7 38543 10 103280000 105830000 Deletion LDB1 Sezary syndrome
8 38544 10 103280000 105830000 Deletion MGEA5 Sezary syndrome
9 38545 10 103280000 105830000 Deletion NEURL Sezary syndrome
10 38546 10 103280000 105830000 Deletion NFKB2 Sezary syndrome
11 38547 10 103280000 105830000 Deletion NT5C2 Sezary syndrome
12 38548 10 103280000 105830000 Deletion PCGF6 Sezary syndrome
13 38549 10 103280000 105830000 Deletion PDCD11 Sezary syndrome
14 38550 10 103280000 105830000 Deletion POLL Sezary syndrome
15 38551 10 103280000 105830000 Deletion PSD Sezary syndrome
16 38552 10 103280000 105830000 Deletion SH3PXD2A Sezary syndrome
17 38553 10 103280000 105830000 Deletion SLK Sezary syndrome
18 38554 10 103280000 105830000 Deletion SUFU Sezary syndrome
19 38555 10 103280000 105830000 Deletion TLX1 Sezary syndrome
20 38556 10 103280000 105830000 Deletion TRIM8 Sezary syndrome
21 39119 10 110240000 112960000 Deletion ADD3 Sezary syndrome
22 39120 10 110240000 112960000 Deletion DUSP5 Sezary syndrome
23 39121 10 110240000 112960000 Deletion MXI1 Sezary syndrome
24 39122 10 110240000 112960000 Deletion PDCD4 Sezary syndrome
25 39123 10 110240000 112960000 Deletion SMC3 Sezary syndrome
26 39709 10 118690000 123210000 Deletion BAG3 Sezary syndrome
27 39710 10 118690000 123210000 Deletion BRWD2 Sezary syndrome
28 39711 10 118690000 123210000 Deletion CASC2 Sezary syndrome
29 39712 10 118690000 123210000 Deletion EIF3S10 Sezary syndrome
30 39713 10 118690000 123210000 Deletion EMX2 Sezary syndrome
31 39714 10 118690000 123210000 Deletion FGFR2 Sezary syndrome
32 39715 10 118690000 123210000 Deletion GFRA1 Sezary syndrome
33 39716 10 118690000 123210000 Deletion HSPA12A Sezary syndrome
34 39717 10 118690000 123210000 Deletion INPP5F Sezary syndrome
35 39718 10 118690000 123210000 Deletion NANOS1 Sezary syndrome
36 39719 10 118690000 123210000 Deletion PRDX3 Sezary syndrome
37 39720 10 118690000 123210000 Deletion PRLHR Sezary syndrome
38 39721 10 118690000 123210000 Deletion RGS10 Sezary syndrome
39 39722 10 118690000 123210000 Deletion TIAL1 Sezary syndrome
40 40284 10 126610000 131820000 Deletion ADAM12 Sezary syndrome
41 40285 10 126610000 131820000 Deletion BCCIP Sezary syndrome
42 40286 10 126610000 131820000 Deletion CTBP2 Sezary syndrome
43 40287 10 126610000 131820000 Deletion DHX32 Sezary syndrome
44 40288 10 126610000 131820000 Deletion DOCK1 Sezary syndrome
45 40289 10 126610000 131820000 Deletion MGMT Sezary syndrome
46 40290 10 126610000 131820000 Deletion MKI67 Sezary syndrome
47 40291 10 126610000 131820000 Deletion MMP21 Sezary syndrome
48 40292 10 126610000 131820000 Deletion PTPRE Sezary syndrome
49 40293 10 126610000 131820000 Deletion ZRANB1 Sezary syndrome
50 42175 10 29840000 33170000 Deletion ARHGAP12 Sezary syndrome

Expression for Sezary's Disease

Search GEO for disease gene expression data for Sezary's Disease.

Pathways for Sezary's Disease

Pathways related to Sezary's Disease according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 TNFRSF1B STAT4 IL7 IL5 IL4 IL2RA
2
Show member pathways
13.64 TNFRSF1B IL7 IL5 IL4 IL2RA IL2
3
Show member pathways
13.49 TNFRSF1B STAT4 IL7 IL5 IL4 IL2RA
4
Show member pathways
13.37 TNFRSF1B STAT4 IL7 IL5 IL4 IL2RA
5
Show member pathways
13.31 TNFRSF1B IL7 IL5 IL4 IL2RA IL2
6
Show member pathways
13.26 TNFRSF1B IL7 IL5 IL4 IL2RA IL2
7 12.82 STAT4 IL7 IL5 IL4 IL2RA IL2
8
Show member pathways
12.73 TNFRSF1B IL7 IL4 IL2RA IL2
9
Show member pathways
12.71 IL5 IL4 IL2RA IL2 IFNA1 CTLA4
10
Show member pathways
12.61 TNFRSF1B IL4 IL2RA IL2 CD28 BCL10
11
Show member pathways
12.59 IL5 IL4 IL2 CTLA4 CD28 BCL10
12
Show member pathways
12.57 STAT4 IL5 IL4 IL2RA IL2 CD28
13
Show member pathways
12.4 STAT4 IL7 IL5 IL4 IL2RA IL2
14
Show member pathways
12.37 IL2RA IL2 CTLA4 CD28 BCL10
15
Show member pathways
12.32 TNFRSF1B IL2RA IL2 CCR4 CCR10
16
Show member pathways
12.25 IL5 IL4 IL2RA IL2 IFNA1
17 12.12 TNFRSF1B STAT4 IL4 IL2RA IL2 IFNA1
18
Show member pathways
12.03 STAT4 IL7 IL4 IL2RA IL2
19
Show member pathways
11.97 STAT4 IL4 IL2RA IL2
20 11.9 IL7 IL5 IL4 IL2RA CD7
21
Show member pathways
11.87 STAT4 IL2 CD28
22 11.86 IL7 IL5 IL4 IL2RA IL2 CD28
23
Show member pathways
11.8 STAT4 IL4 CD28
24 11.75 IL5 IL4 IL2
25
Show member pathways
11.71 IL5 IL4 IL2RA IL2 CTLA4
26
Show member pathways
11.65 IL4 IL2RA IL2
27 11.64 IL7 IL5 IL4 IL2RA IL2 CD7
28
Show member pathways
11.6 STAT4 IL2RA IL2
29
Show member pathways
11.36 TNFRSF1B IL2RA IL2
30 11.3 IL7 IL5 IL4
31 11.3 STAT4 IL5 IL4 IL2RA IL2 CD28
32 11.28 IL2 CTLA4 CD28
33 11.26 IL7 IL5 IL4 IL2
34 11.23 STAT4 IL2RA IL2 CD28
35 11.19 IL5 IL4 IL2
36 10.74 IL5 IL4
37 10.62 TNFRSF1B IL5 IL4 IL2RA IL2 CD28

GO Terms for Sezary's Disease

Cellular components related to Sezary's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 MIR342 MIR223 MIR17 IL7 IL5 IL4
2 external side of plasma membrane GO:0009897 9.35 IL2RA CTLA4 CD28 CCR4 CCR10
3 protein complex involved in cell adhesion GO:0098636 8.62 CTLA4 CD28

Biological processes related to Sezary's Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.03 IL2RA IL2 CTLA4 CD7 CD28 BCL10
2 positive regulation of cell proliferation GO:0008284 10 IL7 IL5 IL4 IL2 DPP4
3 adaptive immune response GO:0002250 9.97 IL2 IFNA1 CTLA4 CD7 BCL10
4 negative regulation of inflammatory response GO:0050728 9.8 TNFRSF1B MIR223 IL4 IL2RA IL2
5 positive regulation of T cell proliferation GO:0042102 9.78 IL4 IL2RA IL2 CD28
6 humoral immune response GO:0006959 9.72 IL7 IFNA1 CD28
7 T cell costimulation GO:0031295 9.7 DPP4 CTLA4 CD28
8 T cell activation GO:0042110 9.67 IL4 DPP4 CD7 CD28
9 regulation of T cell proliferation GO:0042129 9.63 TNFRSF1B CTLA4 CD28
10 positive regulation of B cell proliferation GO:0030890 9.62 IL7 IL5 IL4 IL2
11 negative regulation of immune response GO:0050777 9.61 IL2RA CTLA4
12 positive regulation of isotype switching to IgG isotypes GO:0048304 9.61 IL4 IL2 CD28
13 negative regulation of neuroinflammatory response GO:0150079 9.6 TNFRSF1B IL4
14 positive regulation of immunoglobulin secretion GO:0051024 9.59 IL5 IL2
15 interleukin-2-mediated signaling pathway GO:0038110 9.58 IL2RA IL2
16 negative regulation of T-helper 17 cell differentiation GO:2000320 9.58 IL4 IL2
17 positive regulation of T cell differentiation GO:0045582 9.56 IL7 IL4 IL2RA IL2
18 cytokine-mediated signaling pathway GO:0019221 9.56 TNFRSF1B STAT4 IL7 IL5 IL4 IL2RA
19 negative regulation of lymphocyte proliferation GO:0050672 9.54 IL2RA IL2
20 negative regulation of neutrophil chemotaxis GO:0090024 9.51 MIR223 DPP4
21 regulation of T cell homeostatic proliferation GO:0046013 9.49 IL2RA IL2
22 regulation of regulatory T cell differentiation GO:0045589 9.46 IL2RA IL2 CTLA4 CD28
23 immune response GO:0006955 9.36 TNFRSF1B IL7 IL5 IL4 IL2RA IL2

Molecular functions related to Sezary's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL7 IL5 IL4 IL2
2 kinase activator activity GO:0019209 9.26 IL2 BCL10
3 cytokine receptor binding GO:0005126 9.13 IL7 IL4 IFNA1
4 cytokine activity GO:0005125 9.02 IL7 IL5 IL4 IL2 IFNA1

Sources for Sezary's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....